Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 708

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 708
---
 Subsidiaries have received any notice or other communication from any Governmental Authority alleging any violation of any Health Care Law. (b)All Company Products are in material compliance with all applicable requirements under the Health Care Laws, including all requirements relating to research, storing, testing, record-keeping, reporting, import and export. Except as set forth on Section 4.26 of the Company Disclosure Letter, neither the Company nor its Subsidiaries have received any notice or other communication from any Governmental Authority alleging any violation of such requirements. (c)All studies performed in connection with or as the basis for any approval required for any Company Product (i) have been conducted in accordance, in all material respects, with applicable requirements and Health Care Laws and (ii) have employed in all material respects the procedures and controls generally used by qualified experts in accordance with Health Care Laws. Neither the Company nor its Subsidiaries have received any notice or other written communication from an applicable Governmental Authority requiring the termination or suspension or material modification of any study with respect to any Company Product. Section 4.27 Investment Company; Exchange Act . The Company is not an “investment company” or a Person directly or indirectly “controlled” by or acting on behalf of an “investment company,” in each case within the meaning of the Investment Company Act. Neither the Company nor any Subsidiary is currently (or has previously been) subject to the requirements of Section 12 of the Exchange Act. Section 4.28 Brokers’ Fees . Except as set forth on Section 4.28 of the Company Disclosure Letter, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders’ fee or other commission in connection with the Transactions based upon arrangements made by the Company, any of the Company’s Subsidiaries’ or any of their Affiliates with respect to which SPAC or any of its Affiliates, Merger Sub, the Company or any of the Company’s Subsidiaries has any obligation. Section 4.29 Related Party Transactions . Except as set forth on Section 4.29 of the Company Disclosure Letter, and except for employment relationships and the payment of compensation, benefits and expense reimbursements and advances in the ordinary course of business and pursuant to any Company Benefit Plan, no director, officer or other Affiliate of the Company or any Subsidiary of the Company, to the knowledge of the Company, has, directly or Annex A-38 indirectly: (i)